

AMENDMENTS TO THE CLAIMS

Claim 1.(currently amended) A mouse/human chimeric anti-phencyclidine (PCP) ~~mouse/human~~ monoclonal antibody, comprising:

a full-length chimeric heavy chain and a full-length chimeric light chain, wherein sequence of the full-length chimeric heavy chain comprises a leader sequence of a heavy chain of a murine antibody, a variable domain sequence of the heavy chain of said murine antibody and a human immunoglobulin heavy chain constant domain sequence ~~and a heavy chain variable domain sequence of a murine antibody~~ and wherein sequence of the full-length chimeric light chain comprises a leader sequence of a light chain of a murine antibody, a variable domain sequence of the light chain of said murine antibody and a human immunoglobulin light chain constant domain sequence ~~and a light chain variable domain sequence of a murine antibody, wherein the heavy chain variable domain sequence and the light chain variable domain sequence further comprises a leader sequence.~~

Claim 2. (currently amended) The mouse/human chimeric anti-phencyclidine (PCP) ~~mouse/human~~ monoclonal antibody of claim 1, wherein said human immunoglobulin heavy chain constant domain sequence is constant domain sequence of human IgG heavy chain and said human immunoglobulin

Claim 7. (currently amended) The mouse/human chimeric anti-phencyclidine (PCP) mouse/human monoclonal antibody of claim 6, wherein said full-length chimeric heavy chain consists of ~~comprises~~ DNA of SEQ ID NO. 17.

Claims 8-13. (canceled).

Claim 14. (currently amended) A pharmaceutical composition, comprising the mouse/human chimeric mouse/human anti-phencyclidine (PCP) monoclonal antibody of claim 1 and a pharmaceutically acceptable carrier.

Claims 15-35. (canceled).